Focus Partners Wealth Purchases 3,144 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Focus Partners Wealth boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 245.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,427 shares of the biopharmaceutical company's stock after buying an additional 3,144 shares during the quarter. Focus Partners Wealth's holdings in Alnylam Pharmaceuticals were worth $1,042,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Regeneron Pharmaceuticals Inc. bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $1,045,822,000. Norges Bank bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $577,941,000. Capital Research Global Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 39.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after acquiring an additional 1,245,195 shares during the period. Finally, Marshall Wace LLP grew its stake in shares of Alnylam Pharmaceuticals by 496.6% in the fourth quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after acquiring an additional 315,182 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. UBS Group upped their target price on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. HC Wainwright reissued a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Bank of America boosted their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Finally, Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

Insider Buying and Selling

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares of the company's stock, valued at $3,240,344.36. This trade represents a 10.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Pushkal Garg sold 1,548 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,017,271.63. This represents a 11.44% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Up 0.7%

NASDAQ ALNY opened at $285.31 on Friday. The stock's 50 day simple moving average is $253.73 and its 200 day simple moving average is $253.58. Alnylam Pharmaceuticals, Inc. has a one year low of $146.79 and a one year high of $304.39. The firm has a market cap of $37.20 billion, a PE ratio of -131.48 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The business's quarterly revenue was up 20.2% on a year-over-year basis. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.